| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TAZAROTENE | 208258 | 001 | ANDA | TAZAROTENE | CREAM;TOPICAL | 0.1% | No | No | 2017/04/03 | 2017/04/03 | TARO | Prescription |
| TAZAROTENE | 208662 | 001 | ANDA | TAZAROTENE | CREAM;TOPICAL | 0.1% | No | No | 2017/12/22 | 2017/12/22 | COSETTE | Prescription |
| TAZAROTENE | 211175 | 001 | ANDA | TAZAROTENE | CREAM;TOPICAL | 0.1% | No | No | 2019/01/28 | 2019/01/28 | FOUGERA PHARMS INC | Discontinued |
| TAZAROTENE | 214136 | 001 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.1% | No | No | 2022/09/13 | 2022/09/13 | COSETTE | Prescription |
| TAZAROTENE | 215433 | 001 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.05% | No | No | 2022/09/13 | 2022/09/13 | COSETTE | Prescription |
| TAZAROTENE | 213644 | 001 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.05% | No | No | 2023/03/20 | 2023/03/20 | SOLARIS PHARMA CORP | Prescription |
| TAZAROTENE | 213644 | 002 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.1% | No | No | 2023/03/20 | 2023/03/20 | SOLARIS PHARMA CORP | Prescription |
| HALOBETASOL PROPIONATE; TAZAROTENE | 217190 | 001 | ANDA | HALOBETASOL PROPIONATE;TAZAROTENE | LOTION;TOPICAL | 0.01%;0.045% | No | No | 2023/04/20 (TA) | -- | TARO PHARMS | None (Tentative Approval) |
| TAZAROTENE | 213079 | 001 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.05% | No | No | 2023/04/25 | 2023/04/25 | PADAGIS ISRAEL | Prescription |
| TAZAROTENE | 213079 | 002 | ANDA | TAZAROTENE | GEL;TOPICAL | 0.1% | No | No | 2023/04/25 | 2023/04/25 | PADAGIS ISRAEL | Prescription |
| TAZAROTENE | 217075 | 001 | ANDA | TAZAROTENE | CREAM;TOPICAL | 0.05% | No | No | 2024/07/15 | 2024/07/15 | PADAGIS ISRAEL | Prescription |